Top

Endocrine

Published in:

01-12-2018 | Original Article

Safety and efficiency of ultrasound-guided low power microwave ablation in the treatment of cervical metastatic lymph node from papillary thyroid carcinoma: a mean of 32 months follow-up study

Authors: Dengke Teng, Lei Ding, Yu Wang, Caimei Liu, Yongxu Xia, Hui Wang

Published in: Endocrine | Issue 3/2018

Abstract

Purpose

To evaluate the safety and efficiency of microwave ablation (MWA) with low power of 20 w, respectively, in the treatment of cervical metastatic lymph node (CMLN) from papillary thyroid carcinoma (PTC) with a mean of 32-month follow-up.

Methods

Eleven patients in total with 24 cervical lymph nodes (LNs) diagnosed with CMLN from PTC underwent MWA at a power of 20 w. We recorded images of the LNs under ultrasound first before MWA and 1, 3, 6, 12, months after MWA, and then every 6 months, respectively. The volumes of the LNs were compared before MWA and at each follow-up point after MWA. The thyroglobulin (Tg) test was performed before MWA and 3 months after MWA.

Results

All patients were successfully treated, and they showed no major complications. Before MWA, the mean volume of the LNs was 364.15 ± 306.89 mm³, which decreased to 234.10 ± 230.34 mm³, 107.51 ± 129.47 mm³, 20.88 ± 39.27 mm³, 3.38 ± 12.74 mm³, and completely disappeared at the follow-up point of 1, 3, 6, 12, and 18 months after MWA, respectively. The mean Tg was 11.81 ± 7.50 ng/ml, a data significantly decreased to 0.43 ± 0.11 ng/ml 3 months after MWA (P = 0.000). In the follow-up period, no recurrent lesions were found.

Conclusions

For the treatment of CMLN from PTC, low power MWA showed good safety and efficacy. MWA is likely to be a candidate for patients with high risks or who refuse reoperation.

Available only for authorised users

R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018). https://doi.org/10.3322/caac.21442 CrossRefPubMed

L.G. Morris, R.M. Tuttle, L. Davies, Changing trends in the incidence of thyroid cancer in the United States. JAMA Otolaryngol. Head. Neck Surg. 142(7), 709–711 (2016). https://doi.org/10.1001/jamaoto.2016.0230 CrossRefPubMedPubMedCentral

N.A. Johnson, M.E. Tublin, Postoperative surveillance of differentiated thyroid carcinoma: rationale, techniques, and controversies. Radiology 249(2), 429–444 (2008). https://doi.org/10.1148/radiol.2492071313. 6.798CrossRefPubMed

K.D. Burman, Treatment of recurrent or persistent cervical node metastases in differentiated thyroid cancer: deceptively simple options. J. Clin. Endocrinol. Metab. 97(8), 2623–2625 (2012). https://doi.org/10.1210/jc.2012-2480 CrossRefPubMed

I.D. Hay, G.B. Thompson, C.S. Grant, E.J. Bergstralh, C.E. Dvorak, C.A. Gorman, M.S. Maurer, B. McIver, B.P. Mullan, A.L. Oberg, C.C. Powell, J.A. van Heerden, J.R. Goellner, Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J. Surg. 26(8), 879–885 (2002). https://doi.org/10.1007/s00268-002-6612-1. 2.523CrossRefPubMed

P. Liang, Y. Wang, X. Yu, B. Dong, Malignant liver tumors: treatment with percutaneous microwave ablation--complications among cohort of 1136 patients. Radiology 251(3), 933–940 (2009). https://doi.org/10.1148/radiol.2513081740 CrossRefPubMed

J. Yu, P. Liang, X.L. Yu, Z.G. Cheng, Z.Y. Han, X. Zhang, J. Dong, M.J. Mu, X. Li, X.H. Wang, US-guided percutaneous microwave ablation versus open radical nephrectomy for small renal cell carcinoma: intermediate-term results. Radiology 270(3), 880–887 (2014). https://doi.org/10.1148/radiol.13130275 CrossRefPubMed

M. Li, X. Yu, P. Liang, B. Dong, F. Liu, Ultrasound-guided percutaneous microwave ablation for hepatic malignancy adjacent to the gallbladder. Int J. Hyperth. 31(6), 579–587 (2015). https://doi.org/10.3109/02656736.2015.1014869 CrossRef

L. Sidoff, D.E. Dupuy, Clinical experiences with microwave thermal ablation of lung malignancies. Int. J. Hyperth. 33(1), 25–33 (2017). https://doi.org/10.1080/02656736.2016.1204630 CrossRef

10.

Y. Korkusuz, O.M. Mader, W. Kromen, C. Happel, S. Ahmad, D. Groner, M. Koca, A. Mader, F. Grunwald, H. Korkusuz, Cooled microwave ablation of thyroid nodules: Initial experience. Eur. J. Radiol. 85(11), 2127–2132 (2016). https://doi.org/10.1016/j.ejrad.2016.09.019 CrossRefPubMed

11.

W. Yue, S. Wang, S. Yu, B. Wang, Ultrasound-guided percutaneous microwave ablation of solitary T1N0M0 papillary thyroid microcarcinoma: initial experience. Int J. Hyperth. 30(2), 150–157 (2014). https://doi.org/10.3109/02656736.2014.885590 CrossRef

12.

D. Teng, G. Sui, C. Liu, Y. Wang, Y. Xia, H. Wang, Long-term efficacy of ultrasound-guided low power microwave ablation for the treatment of primary papillary thyroid microcarcinoma: a 3-year follow-up study. J. Cancer Res. Clin. Oncol. (2018). https://doi.org/10.1007/s00432-018-2607-7 CrossRefPubMed

13.

W. Yue, L. Chen, S. Wang, S. Yu, Locoregional control of recurrent papillary thyroid carcinoma by ultrasound-guided percutaneous microwave ablation: A prospective study. Int J. Hyperth. 31(4), 403–408 (2015). https://doi.org/10.3109/02656736.2015.1014433 CrossRef

14.

W.K. Jeong, J.H. Baek, H. Rhim, Y.S. Kim, M.S. Kwak, H.J. Jeong, D. Lee, Radiofrequency ablation of benign thyroid nodules: safety and imaging follow-up in 236 patients. Eur. Radiol. 18(6), 1244–1250 (2008). https://doi.org/10.1007/s00330-008-0880-6 CrossRefPubMed

15.

J.E. Shin, J.H. Baek, J.H. Lee, Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers: current status and challenges. Curr. Opin. Oncol. 25(1), 14–19 (2013). https://doi.org/10.1097/CCO.0b013e32835a583d. 4.614CrossRefPubMed

16.

B.D. Lewis, I.D. Hay, J.W. Charboneau, B. McIver, C.C. Reading, J.R. Goellner, Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am. J. Roentgenol. 178(3), 699–704 (2002). https://doi.org/10.2214/ajr.178.3.1780699 CrossRefPubMed

17.

A. Heilo, E. Sigstad, K.H. Fagerlid, O.I. Haskjold, K.K. Groholt, A. Berner, T. Bjoro, L.H. Jorgensen, Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 96(9), 2750–2755 (2011). https://doi.org/10.1210/jc.2010-2952 CrossRefPubMed

18.

J.P. Guenette, J.M. Monchik, D.E. Dupuy, Image-guided ablation of postsurgical locoregional recurrence of biopsy-proven well-differentiated thyroid carcinoma. J. Vasc. Interv. Radiol. 24(5), 672–679 (2013). https://doi.org/10.1016/j.jvir.2013.02.001. 2.57CrossRefPubMed

19.

I.D. Hay, R.A. Lee, C. Davidge-Pitts, C.C. Reading, J.W. Charboneau, Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected “recurrent” neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy. Surgery 154(6), 1448–1454 (2013). https://doi.org/10.1016/j.surg.2013.07.007 CrossRefPubMed

20.

T.E. Fontenot, A. Deniwar, P. Bhatia, Z. Al-Qurayshi, G.W. Randolph, E. Kandil, Percutaneous ethanol injection vs reoperation for locally recurrent papillary thyroid cancer: a systematic review and pooled analysis. JAMA Otolaryngol. Head Neck Surg. 141(6), 512–518 (2015). https://doi.org/10.1001/jamaoto.2015.0596 CrossRefPubMed

21.

D.E. Dupuy, J.M. Monchik, C. Decrea, L. Pisharodi, Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. Surgery 130(6), 971–977 (2001). https://doi.org/10.1067/msy.2001.118708. 3.309CrossRefPubMed

22.

J.M. Monchik, G. Donatini, J. Iannuccilli, D.E. Dupuy, Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. ANN SURG 244(2), 296–304 (2006). https://doi.org/10.1097/01.sla.0000217685.85467.2d. 8.569CrossRefPubMedPubMedCentral

23.

J.H. Baek, Y.S. Kim, J.Y. Sung, H. Choi, J.H. Lee, Locoregional control of metastatic well-differentiated thyroid cancer by ultrasound-guided radiofrequency ablation. AJR Am. J. Roentgenol. 197(2), W331–336 (2011). https://doi.org/10.2214/ajr.10.5345 CrossRefPubMed

24.

K.W. Park, J.H. Shin, B.K. Han, E.Y. Ko, J.H. Chung, Inoperable symptomatic recurrent thyroid cancers: preliminary result of radiofrequency ablation. Ann. Surg. Oncol. 18(9), 2564–2568 (2011). https://doi.org/10.1245/s10434-011-1619-1. 3.655CrossRefPubMed

25.

J.H. Kim, W.S. Yoo, Y.J. Park, D.J. Park, T.J. Yun, S.H. Choi, C.H. Sohn, K.E. Lee, M.W. Sung, Y.K. Youn, K.H. Kim, B.Y. Cho, Efficacy and safety of radiofrequency ablation for treatment of locally recurrent thyroid cancers smaller than 2 cm. Radiology 276(3), 909–918 (2015). https://doi.org/10.1148/radiol.15140079. 6.798CrossRefPubMed

26.

H.K. Lim, J.H. Baek, J.H. Lee, W.B. Kim, T.Y. Kim, Y.K. Shong, S.J. Hong, Efficacy and safety of radiofrequency ablation for treating locoregional recurrence from papillary thyroid cancer. Eur. Radiol. 25(1), 163–170 (2015). https://doi.org/10.1007/s00330-014-3405-5. 3.64CrossRefPubMed

27.

Y. Guang, Y. Luo, Y. Zhang, M. Zhang, N. Li, Y. Zhang, J. Tang, Efficacy and safety of percutaneous ultrasound guided radiofrequency ablation for treating cervical metastatic lymph nodes from papillary thyroid carcinoma. J. Cancer Res. Clin. Oncol. 143(8), 1555–1562 (2017). https://doi.org/10.1007/s00432-017-2386-6 CrossRefPubMed

28.

G. Mauri, L. Cova, T. Tondolo, T. Ierace, A. Baroli, E. Di Mauro, C.M. Pacella, S.N. Goldberg, L. Solbiati, Percutaneous laser ablation of metastatic lymph nodes in the neck from papillary thyroid carcinoma: preliminary results. J. Clin. Endocrinol. Metab. 98(7), E1203–1207 (2013). https://doi.org/10.1210/jc.2013-1140 CrossRefPubMed

29.

E. Papini, G. Bizzarri, A. Bianchini, D. Valle, I. Misischi, R. Guglielmi, M. Salvatori, L. Solbiati, A. Crescenzi, C.M. Pacella, H. Gharib, Percutaneous ultrasound-guided laser ablation is effective for treating selected nodal metastases in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 98(1), E92–97 (2013). https://doi.org/10.1210/jc.2012-2991 CrossRefPubMed

30.

G. Mauri, L. Cova, T. Ierace, A. Baroli, E. Di Mauro, C.M. Pacella, S.N. Goldberg, L. Solbiati, Treatment of metastatic lymph nodes in the neck from papillary thyroid carcinoma with percutaneous laser ablation. Cardiovasc. Interv. Radiol. 39(7), 1023–1030 (2016). https://doi.org/10.1007/s00270-016-1313-6 CrossRef

31.

W. Zhou, L. Zhang, W. Zhan, S. Jiang, Y. Zhu, S. Xu, Percutaneous laser ablation for treatment of locally recurrent papillary thyroid carcinoma<15 mm. Clin. Radiol. 71(12), 1233–1239 (2016). https://doi.org/10.1016/j.crad.2016.07.010. 2.151CrossRefPubMed

32.

B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1–133 (2016). https://doi.org/10.1089/thy.2015.0020. 3.784CrossRefPubMedPubMedCentral

33.

N. Bhardwaj, A.D. Strickland, F. Ahmad, L. Atanesyan, K. West, D.M. Lloyd, A comparative histological evaluation of the ablations produced by microwave, cryotherapy and radiofrequency in the liver. Pathology 41(2), 168–172 (2009). https://doi.org/10.1080/00313020802579292. 2.968CrossRefPubMed

34.

W. Shady, E.N. Petre, K.G. Do, M. Gonen, H. Yarmohammadi, K.T. Brown, N.E. Kemeny, M. D’Angelica, P.T. Kingham, S.B. Solomon, C.T. Sofocleous, Percutaneous microwave versus radiofrequency ablation of colorectal liver metastases: ablation with clear margins (A0) provides the best local tumor control. J. Vasc. Interv. Radiol. 29(2), 268–275.e261 (2018). https://doi.org/10.1016/j.jvir.2017.08.021. 2.57CrossRefPubMed

35.

B. Feng, P. Liang, Z. Cheng, X. Yu, J. Yu, Z. Han, F. Liu, Ultrasound-guided percutaneous microwave ablation of benign thyroid nodules: experimental and clinical studies. Eur. J. Endocrinol. 166(6), 1031–1037 (2012). https://doi.org/10.1530/EJE-11-0966 CrossRefPubMed

36.

B. Wang, Z.Y. Han, J. Yu, Z. Cheng, F. Liu, X.L. Yu, C. Chen, J. Liu, P. Liang, Factors related to recurrence of the benign non-functioning thyroid nodules after percutaneous microwave ablation. Int. J. Hyperthermia 33(4), 459–464 (2017). https://doi.org/10.1080/02656736.2016.1274058 CrossRefPubMed

37.

H. Korkusuz, C. Happel, D.A. Koch, F. Gruenwald, Combination of ultrasound-guided percutaneous microwave ablation and radioiodine therapy in benign thyroid disease: A 3-month follow-up study. Rofo 188(1), 60–68 (2016). https://doi.org/10.1055/s-0041-106538 CrossRefPubMed

Title: Safety and efficiency of ultrasound-guided low power microwave ablation in the treatment of cervical metastatic lymph node from papillary thyroid carcinoma: a mean of 32 months follow-up study
Authors: Dengke Teng
Lei Ding
Yu Wang
Caimei Liu
Yongxu Xia
Hui Wang
Publication date: 01-12-2018
Publisher: Springer US
Published in: Endocrine / Issue 3/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-018-1711-4

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Safety and efficiency of ultrasound-guided low power microwave ablation in the treatment of cervical metastatic lymph node from papillary thyroid carcinoma: a mean of 32 months follow-up study

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Graves’ Orbitopathy: do not give it for granted

Negative-pressure wound therapy for management of chronic neuropathic noninfected diabetic foot ulcerations – short-term efficacy and long-term outcomes

Autoimmune pituitary involvement in Prader–Willi syndrome: new perspective for further research

Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up

Hyperinsulinemia precedes insulin resistance in offspring rats exposed to angiotensin II type 1 autoantibody in utero

SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page